LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Mineralys Therapeutics, Inc. on September 6 and set a price target of $44.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the potential of Mineralys Therapeutics, Inc. The recent Phase III data on baxdrostat, a drug under evaluation for hypertension, has shown promising results, reinforcing the clinical potential of aldosterone synthase inhibitors (ASIs) in treating this condition. This positions Mineralys favorably in the market, particularly with its own product, lorundrostat, which continues to demonstrate a strong profile in comparison to competitors.
Moreover, the positive reception of these clinical results at a major conference, such as the European Society of Cardiology Congress, and the publication in a reputable journal like the New England Journal of Medicine, further validate the company’s research efforts. The combination of these factors, along with a favorable market environment for hypertension treatments, supports the Buy rating, with a price target set at $44.00, indicating a strong potential for growth and investor returns.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 21.9% and a 51.83% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Mineralys Therapeutics, Inc., and Eledon Pharmaceuticals.
In another report released on September 4, Bank of America Securities also reiterated a Buy rating on the stock with a $43.00 price target.